BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Pancreatic cancer AND uPA AND Prognosis
17 results:

  • 1. Urokinase plasminogen activator induces epithelial-mesenchymal and metastasis of pancreatic cancer through plasmin/MMP14/TGF-β axis, which is inhibited by 4-acetyl-antroquinonol B treatment.
    Wu CZ; Chu YC; Lai SW; Hsieh MS; Yadav VK; Fong IH; Deng L; Huang CC; Tzeng YM; Yeh CT; Chen JS
    Phytomedicine; 2022 Jun; 100():154062. PubMed ID: 35366491
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. The Urokinase Plasminogen Activation System in pancreatic cancer: Prospective Diagnostic and Therapeutic Targets.
    Kumar AA; Buckley BJ; Ranson M
    Biomolecules; 2022 Jan; 12(2):. PubMed ID: 35204653
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. SerpinB2 regulates stromal remodelling and local invasion in pancreatic cancer.
    Harris NLE; Vennin C; Conway JRW; Vine KL; Pinese M; Cowley MJ; Shearer RF; Lucas MC; Herrmann D; Allam AH; Pajic M; Morton JP; ; Biankin AV; Ranson M; Timpson P; Saunders DN
    Oncogene; 2017 Jul; 36(30):4288-4298. PubMed ID: 28346421
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. The Transient Receptor Potential Melastatin 7 Channel Regulates pancreatic cancer Cell Invasion through the Hsp90α/upa/MMP2 pathway.
    Rybarczyk P; Vanlaeys A; Brassart B; Dhennin-Duthille I; Chatelain D; Sevestre H; Ouadid-Ahidouch H; Gautier M
    Neoplasia; 2017 Apr; 19(4):288-300. PubMed ID: 28284058
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. Can MDCT or EUS features predict the histopathological grading scheme of pancreatic neuroendocrine neoplasms?
    Zhu H; Ying L; Tang W; Yang X; Sun B
    Radiol Med; 2017 May; 122(5):319-326. PubMed ID: 28176217
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. miR-193b directly targets STMN1 and upa genes and suppresses tumor growth and metastasis in pancreatic cancer.
    Li J; Kong F; Wu K; Song K; He J; Sun W
    Mol Med Rep; 2014 Nov; 10(5):2613-20. PubMed ID: 25215905
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. Multifunctional roles of urokinase plasminogen activator (upa) in cancer stemness and chemoresistance of pancreatic cancer.
    Asuthkar S; Stepanova V; Lebedeva T; Holterman AL; Estes N; Cines DB; Rao JS; Gondi CS
    Mol Biol Cell; 2013 Sep; 24(17):2620-32. PubMed ID: 23864708
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. Gambogic acid-loaded magnetic Fe(3)O(4) nanoparticles inhibit Panc-1 pancreatic cancer cell proliferation and migration by inactivating transcription factor ETS1.
    Wang C; Zhang H; Chen Y; Shi F; Chen B
    Int J Nanomedicine; 2012; 7():781-7. PubMed ID: 22393285
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. Prognostic significance of growth factors and the urokinase-type plasminogen activator system in pancreatic ductal adenocarcinoma.
    Xue A; Scarlett CJ; Jackson CJ; Allen BJ; Smith RC
    Pancreas; 2008 Mar; 36(2):160-7. PubMed ID: 18376307
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. High expression of plasminogen activator inhibitor-2 (PAI-2) is a predictor of improved survival in patients with pancreatic adenocarcinoma.
    Smith R; Xue A; Gill A; Scarlett C; Saxby A; Clarkson A; Hugh T
    World J Surg; 2007 Mar; 31(3):493-502; discussion 503. PubMed ID: 17219285
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. Expression of E-cadherin and upa and their association with the prognosis of pancreatic cancer.
    Shin SJ; Kim KO; Kim MK; Lee KH; Hyun MS; Kim KJ; Choi JH; Song HS
    Jpn J Clin Oncol; 2005 Jun; 35(6):342-8. PubMed ID: 15937032
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. Significant overexpression of urokinase-type plasminogen activator in pancreatic adenocarcinoma using real-time quantitative reverse transcription polymerase chain reaction.
    Nielsen A; Scarlett CJ; Samra JS; Gill A; Li Y; Allen BJ; Smith RC
    J Gastroenterol Hepatol; 2005 Feb; 20(2):256-63. PubMed ID: 15683429
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. CD95 and TRAF2 promote invasiveness of pancreatic cancer cells.
    Trauzold A; Röder C; Sipos B; Karsten K; Arlt A; Jiang P; Martin-Subero JI; Siegmund D; Müerköster S; Pagerols-Raluy L; Siebert R; Wajant H; Kalthoff H
    FASEB J; 2005 Apr; 19(6):620-2. PubMed ID: 15670977
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. Evaluation of urinary plasminogen activator, its receptor, matrix metalloproteinase-9, and von Willebrand factor in pancreatic cancer.
    Harvey SR; Hurd TC; Markus G; Martinick MI; Penetrante RM; Tan D; Venkataraman P; DeSouza N; Sait SN; Driscoll DL; Gibbs JF
    Clin Cancer Res; 2003 Oct; 9(13):4935-43. PubMed ID: 14581368
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. Aspirin inhibits highly invasive prostate cancer cells.
    Lloyd FP; Slivova V; Valachovicova T; Sliva D
    Int J Oncol; 2003 Nov; 23(5):1277-83. PubMed ID: 14532966
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. DPC4/SMAD4 mediated tumor suppression of colon carcinoma cells is associated with reduced urokinase expression.
    Schwarte-Waldhoff I; Klein S; Blass-Kampmann S; Hintelmann A; Eilert C; Dreschers S; Kalthoff H; Hahn SA; Schmiegel W
    Oncogene; 1999 May; 18(20):3152-8. PubMed ID: 10340387
    [TBL] [Abstract] [Full Text] [Related]  

  • 17. Prognostic significance of three novel biologic factors in a clinical trial of adjuvant therapy for node-negative breast cancer.
    Yamashita J; Ogawa M; Sakai K
    Surgery; 1995 Jun; 117(6):601-8. PubMed ID: 7778023
    [TBL] [Abstract] [Full Text] [Related]  


    of 1.